Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Emerson

Showing results (241-250 of 247) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 247 results.
The New England Journal of Medicine|March 31, 2025
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 DiabetesDarren K McGuire, Nikolaus Marx, Sharon L Mulvagh, et al.
JAMA Cardiology|March 25, 2026
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical TrialSharon L Mulvagh, Silvio E Inzucchi, Nikolaus Marx, et al.
Diabetes Care|December 11, 2025
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized TrialJohannes F E Mann, Nikolaus Marx, John E Deanfield, et al.
Circulation|March 29, 2025
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized TrialNikolaus Marx, John E Deanfield, Johannes F E Mann, et al.
JAMA Internal Medicine|February 2, 2026
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical TrialRodica Pop-Busui, Søren Rasmussen, John E Deanfield, et al.
Hepatology (Baltimore, Md.)|October 27, 2005
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosisBurton Combes, Scott S Emerson, Nancy L Flye, et al.
Ambio|February 15, 2002
A new vision of ocean biogeochemistry after a decade of the Joint Global Ocean Flux Study (JGOFS)R Anderson, D Archer, U Bathmann, et al.
Pageof 25

Showing results (241-250 of 247) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 247 results.
The New England Journal of Medicine|March 31, 2025
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 DiabetesDarren K McGuire, Nikolaus Marx, Sharon L Mulvagh, et al.
JAMA Cardiology|March 25, 2026
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical TrialSharon L Mulvagh, Silvio E Inzucchi, Nikolaus Marx, et al.
Diabetes Care|December 11, 2025
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized TrialJohannes F E Mann, Nikolaus Marx, John E Deanfield, et al.
Circulation|March 29, 2025
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized TrialNikolaus Marx, John E Deanfield, Johannes F E Mann, et al.
JAMA Internal Medicine|February 2, 2026
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical TrialRodica Pop-Busui, Søren Rasmussen, John E Deanfield, et al.
Hepatology (Baltimore, Md.)|October 27, 2005
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosisBurton Combes, Scott S Emerson, Nancy L Flye, et al.
Ambio|February 15, 2002
A new vision of ocean biogeochemistry after a decade of the Joint Global Ocean Flux Study (JGOFS)R Anderson, D Archer, U Bathmann, et al.
Pageof 25